Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,582
datasets available to search
ShareScore release 0.9.0
Dataset results
7,582 results for “clinical study”
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study
GEO Series GSE18553. Homo sapiens. 7 samples. Type: Expression profiling by array.
A human transcriptome array for high-throughput clinical studies (with a comparison to RNA-seq technology)
GEO Series GSE26118. Homo sapiens. 24 samples. Type: Expression profiling by array; Expression profiling by high throughput sequencing.
DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Agilent Expression Study)
GEO Series GSE22866. Homo sapiens. 46 samples. Type: Expression profiling by array.
Study of the consistency, comparability and identity of different Dendritic cells productions for clinical use
GEO Series GSE31195. Homo sapiens. 48 samples. Type: Expression profiling by array.
Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer’s disease
GEO Series GSE255718. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Longitudinal transcriptional pediatric SLE study with clinical parameters
GEO Series GSE65391. Homo sapiens. 996 samples. Type: Expression profiling by array.
Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: Clinical safety, efficacy and correlative anal
GEO Series GSE311458. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation
GEO Series GSE114382. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Role of epigenetics in the clinical evolution of COVID-19 disease. Epigenome-wide association study identifies markers of severe outcome.
GEO Series GSE199591. Homo sapiens. 187 samples. Type: Methylation profiling by genome tiling array.
Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson’s disease: A randomized double-blind prospective study [RNA-Seq]
GEO Series GSE296011. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
Redefining the Relevance of Established Cancer Cell Lines to the Study of Clinical Anti-Cancer Drug Resistance
GEO Series GSE30034. Homo sapiens. 228 samples. Type: Expression profiling by RT-PCR.
Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer - The Piedmont Study
GEO Series GSE232569. Homo sapiens. 95 samples. Type: Expression profiling by high throughput sequencing.
Spliceosome mutations are associated with clinical response in a Phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
GEO Series GSE239678. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
Data from: Identifying the effects of an upgraded 'fever clinic' on COVID-19 control and the workload of emergency department: a retrospective study in a tertiary hospital in China
<p>Objectives: COVID-19 started spreading widely in China. Outpatient fever clinics (FC),were upgraded to serve for COVID-19 screening and prevention of disease transmission in large tertiary hospitals in China. We aimed to evaluate the effect of upgrading the FC system on rates of nosocomial COVID-19 infection and ED patient attendance at PUMCH Methods: The FC of PUMCH was upgraded on January 20, 2020. We performed a retrospective study of patients presenting to the FC between December 12, 2019 and February 29, 2020. January 20, 2020 was the date when COVID-19 was declared an outbreak in Beijing. Two groups of data were collected and subsequently compared with each other: The first group of data was collected within 40 days before January 20, 2020; The second group of data was collected within 40 days after January 20, 2020. All necessary data, including patient baseline information, diagnosis, follow-up conditions, and the transfer records between the FC and ED were collected and analyzed. Results: 6,365 patients were screened in the FC, among whom 2,912 patients were screened before January 21, 2020, while 3,453 were screened afterward. Screening results showed that upper respiratory infection was the major disease associated with fever. After the outbreak of COVID-19, the number of patients who were transferred from the FC to ED decreased significantly [39.21% vs 15.75%, p<0.001], and patients generally spent more time in the FC [55 vs 203minutes, p, compared with before the outbreak. For critically ill patients waiting for their screening results, the total length of stay in the FC was 22minutes before the outbreak, compared with 442minutes after the outbreak Conclusion: The workload of the FC increased significantly after the COVID-19 outbreak. New protocols regarding the use of FC likely helped prevent the spread of COVID-19 l. The upgraded FC reduce the burden on the ED</p>
Efficacy and safety evaluation of a new antidepressant drug agomelatine in the treatment of post-stroke depression: a single-center clinical study
<p><b><span>Objective: </span></b>To compare the effects of agomelatine and sertraline hydrochloride on the clinical efficacy, neurocytokine and monoamine transmitter metabolism in patients with post-stroke depression. </p> <p><b><span>Methods:</span></b> A total of 94 patients with post-stroke depression admitted to our hospital from July 2015 to September 2018 were randomly divided into a test group and a control group with 47 cases each. The experimental group was treated with agomelatine 25 mg/d orally, which was increased to 50 mg/d after 1 week, and the control group was treated with sertraline hydrochloride 50 mg/d. The two groups were treated continuously for 8 weeks. The clinical efficacy, the incidence of adverse reactions and the Hamilton Depression Scale (HAMD) before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) score, BI index, and neurocytokines were compared between the two groups. Derived Neurotrophic Factor: BDNF; Nerve Growth Factor: NGF), Monoamine Transmitter Metabolism (5-Hydroxytryptamine: 5-HT; 5-Hydroxyindoleacetic acid: 5-HIAA; Norepinephrine: NE) changes.</p> <p><b><span>Results:</span></b> After treatment, the total effective rates of the experimental group and the control group were 82.97% (39 cases/47 cases) and 80.85% (38 cases and 47 cases), respectively, and the difference was not statistically significant (P>0.05). After treatment, there was no statistical difference between the test group and the control group in HAMD score, NIHSS score, and BI index (P>0.05). After treatment, there was no statistically significant difference between the test group and the control group in BDNF, NGF, 5-HT, 5-HIAA and NE (P>0.05). The incidence of adverse reactions in the experimental group and the control group were 17.02% and 19.14%, respectively, and the difference was not statistically significant (P>0.05).</p> <p><b><span>Conclusion: </span></b>Agomelatine and sertraline hydrochloride have the same clinical efficacy in the treatment of post-stroke depression, and the adverse reactions are relatively mild.</p>
Data from: Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study
Introduction: Although aspiration pneumonia is the most common complication of progressive supranuclear palsy (PSP), the clinical impact of aspiration pneumonia on disease course and survival has not been fully estimated. Thus, we retrospectively analyzed the prognostic factors and clinical consequences of pneumonia in PSP. Methods: The clinical course of patients with aspiration pneumonia was surveyed. The association between baseline clinical features (2 years from disease onset) and latency to the initial development of pneumonia was investigated using survival time and Cox regression analyses. Results: Ninety patients with a clinical diagnosis of PSP were observed for 5.1±3.8 years (mean±SD), and 22 had aspiration pneumonia. Subsequently, 20 patients (91%) had to discontinue oral feeding entirely and 13 (59%) died, whereas, of 68 patients without pneumonia, only three patients (4%) died. Time to initial development of pneumonia was strongly correlated with survival time (Spearman R = 0.92, P<0.001), with a mean latency of 2.3 years to death. Among baseline clinical features, early fall episodes and cognitive decline were significant predictors of pneumonia (P = 0.001 and P<0.001, respectively, log rank test). Cox regression analysis demonstrated that early fall episodes (adjusted hazard ratio: 3.9, 95% confidence interval: 1.2–12.5, P = 0.03) and cognitive decline (adjusted hazard ratio: 5.2, 95% confidence interval: 1.4–19.3, P = 0.02) independently predicted pneumonia. By contrast, dysphagia was not associated with pneumonia (P = 0.2, log rank test). Conclusion: Initial development of pneumonia indicates an unfavorable clinical course and predicts survival time (mean survival time 2.3 years). Patients with early falls and cognitive decline were at high risk of early development of pneumonia.
Data from: Clinical factors associated with long-term complete remission versus poor response to chemotherapy in HIV-infected children and adolescents with Kaposi sarcoma receiving bleomycin and vincristine: a retrospective observational study
Kaposi sarcoma (KS) is the most common HIV-associated malignancy in children and adolescents in Africa. Pediatric KS is distinct from adult disease. We evaluated the clinical characteristics associated with long-term outcomes. We performed a retrospective observational analysis of 70 HIV-infected children and adolescents with KS less than 18 years of age diagnosed between 8/2010 and 6/2013 in Lilongwe, Malawi. Local first-line treatment included bleomycin and vincristine plus nevirapine-based highly active anti-retroviral therapy (HAART). Median age was 8.6 years (range 1.7–17.9); there were 35 females (50%). Most common sites of presentation were: lymph node (74%), skin (59%), subcutaneous nodules (33%), oral (27%), woody edema (24%), and visceral (16%). Eighteen (26%) presented with lymphadenopathy only. Severe CD4 suppression occurred in 28%. At time of KS diagnosis, 49% were already on HAART. Overall, 28% presented with a platelet count < 100 x 109/L and 37% with hemoglobin < 8 g/dL. The 2-year event-free (EFS) and overall survival (OS) were 46% and 58% respectively (median follow-up 29 months, range 15–50). Multivariable analysis of risk of death and failure to achieve EFS demonstrated that visceral disease (odds ratios [OR] 19.08 and 11.61, 95% CI 2.22–163.90 and 1.60–83.95 respectively) and presenting with more than 20 skin/oral lesions (OR 9.57 and 22.90, 95% CI 1.01–90.99 and 1.00–524.13 respectively) were independent risk factors for both. Woody edema was associated with failure to achieve EFS (OR 7.80, 95% CI 1.84–33.08) but not death. Univariable analysis revealed that lymph node involvement was favorable for EFS (OR 0.28, 95% CI 0.08–0.99), while T1 TIS staging criteria, presence of cytopenias, and severe immune suppression were not associated with increased mortality. Long-term complete remission is achievable in pediatric KS, however outcomes vary according to clinical presentation. Based on clinical heterogeneity, treatment according to risk-stratification is necessary to improve overall outcomes.
Clinical usability study of a transcranial direct current stimulation for primary dysmenorrhea: a randomized controlled trial
Open the record for dataset details and reuse information.
The impact of obesity on orthodontic treatment outcome in adolescents: a prospective clinical cohort study
<p>Dataset for all analyses of the paper</p>
Clinical outcomes in multifocal motor neuropathy: a combined cross-sectional and follow-up study
Objective <p>To assess the clinical course of multifocal motor neuropathy (MMN) in a large cohort of patients and to identify predictive factors of a progressive disease course.</p> Methods <p>Between May 2015 and February 2016, we collected clinical data from 100 patients with MMN of whom 60 had participated in a nationwide cross-sectional cohort study in 2007. We documented clinical characteristics using standardized questionnaires and performed a standardized neurological examination. We used multiple linear regression analysis to identify factors that correlated with worse outcome.</p> Results <p>We found that age of diagnosis (45.2 <i>vs.</i> 48.6 years, <i>p</i><0.02) significantly increased between 2007 and 2015-2016, whereas diagnostic delay decreased with 15 months. Seven out of ten outcome measures deteriorated over time (all <i>p</i><0.01). Patients who had a lower MRC sum score and absence of one or more reflexes at the baseline visit showed a greater functional loss at follow up (<i>p</i>=0.007 and <i>p</i>=0.016).</p> Conclusions <p>Our study shows that MMN is a progressive disease. Although 87% of patients received maintenance treatment, muscle strength, reflexes, vibration sense, and the Self-Evaluation Scale significantly deteriorated over time. Lower MRC sum score and absence of reflexes predicted a more progressive disease course.</p> Classification of evidence <p>This study provides Class II evidence that lower MRC sum score and the absence of reflexes predict a more progressive disease course in patients with MMN.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.